Structure-Indicated LC-MS/MS Bioanalysis of Therapeutic Antibodies.

This study focuses on structure-indicated lc-ms/ms bioanalysis of therapeutic antibodies.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the biopharmaceutical field. Monoclonal antibodies bind to Protein A/G resin with 100 nm-diameter pores, which orients the Fab toward the reaction solution. Then, they can be proteolyzed using trypsin immobilized on the surface of 200 nm-diameter nanoparticles. The difference between the two particle diameters allows Fab-selective proteolysis by limiting trypsin access to the... Research Background and Significance Therapeutic monoclonal antibodies (mAbs) have become pivotal in modern biopharmaceutical treatments due to their specificity and targeted mechanisms of action. Accurate bioanalysis of these large biomolecules is essential for pharmacokinetic studies, quality control, and ensuring therapeutic efficacy and safety. However, the structural complexity and heterogeneity of antibodies pose significant analytical challenges, necessitating innovative methodologies that provide both specificity and sensitivity. The study by Iwamoto and Shimada (2022) introduces a structure-indicated LC-MS/MS bioanalytical approach that leverages the selective proteolysis of monoclonal antibodies based on Fab orientation. This method addresses limitations inherent in conventional tryptic digestion and peptide mapping by selectively targeting the Fab region, enabling refined structural insights and enhanced assay precision. The integration of high-performance liquid chromatography (HPLC) with mass spectrometry underpins the analytical robustness required for biopharmaceutical applications. Experimental Design and Methodology The experimental design centers on a novel sample preparation